Using the PEG framework with analyst consensus forward EPS growth of 25.0% plus 3.3% dividend yield, MetLife, Inc. has a fair value of $244.59 based on NTM EPS (FY2026) of $9.78. The current PEG ratio is 0.23.
PEG < 1 = bargain, 1–1.5 = fair, > 2 = expensive.
Growth above 25% is capped — hypergrowth may not be sustainable long-term.
| EPS Growth RateForward | 27.9% |
| Dividend Yield | +3.3% |
| Adjusted Growth (clamped 8–25%)Clamped | 25.0% |
| Fair P/E | 25.0x |
| NTM EPS (FY2026) | $9.78 |
| Fair Value | $244.59 |
| Period | EPS Est. | Growth | Analysts |
|---|---|---|---|
| FY2025 (actual) | $4.80 | — | — |
| FY2026E | $9.78 | +103.8% | 7 |
| FY2027E | $10.93 | +11.8% | 7 |
| FY2028E | $12.30 | +12.5% | 4 |
| FY2029E | $12.85 | +4.5% | 3 |
4Y Forward EPS CAGR: 27.9%
| Year | Net Income | EPS | YoY |
|---|
The PEG Fair Value uses the Price/Earnings-to-Growth framework. A stock is fairly valued when its P/E ratio equals its earnings growth rate (PEG = 1.0). This model adds dividend yield to the growth rate per the original PEGY formula.
Growth rate priority: analyst consensus forward EPS CAGR (when ≥ 3 analysts cover the stock), falling back to historical EPS CAGR. Using EPS rather than net income avoids distortion from share buybacks. The growth rate is clamped between 8% and 25% — below 8% would undervalue stable earners, while above 25% would overvalue unsustainable spikes.
| FY2021 | $6.9B | $7.65 | — |
| FY2022 | $5.3B | $6.30 | -17.6% |
| FY2023 | $1.6B | $1.81 | -71.3% |
| FY2024 | $4.4B | $5.94 | +228.2% |
| FY2025 | $3.4B | $4.80 | -19.2% |
4Y Historical EPS CAGR: -11.0%